Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Casein phosphopeptide amorphous calcium phosphate (CPP-ACP), often marketed under the trademark RECALDENT, is a bioactive milk-derived protein complex used in preventive dentistry. It consists of casein phosphopeptides (CPP) that bind and stabilize calcium and phosphate ions in an amorphous, non-crystalline state (ACP). This complex adheres to tooth surfaces, dental plaque, and surrounding soft tissues, creating a reservoir of bioavailable calcium and phosphate. By maintaining a state of supersaturation relative to tooth enamel, CPP-ACP buffers plaque pH, inhibits demineralization, and promotes the remineralization of early non-cavitated carious lesions (white spot lesions). It is commonly used in topical pastes, varnishes (often in combination with fluoride), and chewing gums to treat dental caries and dentin hypersensitivity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on casein phosphopeptide amorphous calcium phosphate.